Different classes of RNA-based molecules have been designed as targeted therapies for precise modulation of transcript or protein expression in Fragile X Syndrome (FXS), MECP2 duplication syndrome (MDS), Angelman syndrome (AS), CHD8-related ASD, and distinct genetic forms of DEEs (Table 1). This evidence concerns the gene MECP2 and fragile X syndrome.